Oxygen Supplementation
OtherOxygen delivery was continuous by mask at 40%
NCT Number: NCT02661802
The purpose of this study was to evaluate the acute effects of oxygen supplementation during a submaximal exercise test in patients with Eisenmenger's Syndrome.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Patients with Eisenmenger's syndrome were submitted to a submaximal exercise test (six-minute walking test) with and without supplemental oxygen. The distance walked during the two tests were compared to assess the impact of oxygen supplementation on the walking distance.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oxygen delivery was continuous by mask at 40%
Time frame: At enrollment
Distance walked during the six-minute walk tests with and without oxygen supplementation were recorded and compared to each other to establish the impact of the intervention.
Federal University of São Paulo
Other
Acute Effects of 40% Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03626688
Cardiovascular Diseases, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT01273259
Cardiovascular Diseases, Chronic Disease
Bordeaux, France
View Trial DetailsNCT00581087
Cardiovascular Diseases, Chronic Disease
Bordeaux, France
View Trial DetailsNCT00595049
Cardiovascular Diseases, Connective Tissue Diseases
Camperdown, Australia
View Trial Details